Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

(Reuters) -Shares of Gilead rose nearly 3% after the U.S. Supreme Court on Friday preserved a key element of the Obamacare ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Before Gilead’s rise, the world in The Handmaid’s Tale was already falling apart. Food shortage, political unrest, environmental disasters — it was all there, bubbling just under the surface.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health insurers to ...